Bevacizumab Injection（Boyounuo^®）

Boyounuo^® is a biosimilar to Avastin^®.

Indications:

• Metastatic Colorectal Cancer：
  Bevacizumab in combination with fluoropyrimidine‑based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer.
• Advanced, Metastatic, or Recurrent Non‑Small Cell Lung Cancer：
  Bevacizumab in combination with platinum‑based chemotherapy is used as first‑line treatment for patients with unresectable advanced, metastatic, or recurrent non‑squamous non‑small cell lung cancer.
• Recurrent Glioblastoma：
  Bevacizumab is indicated for the treatment of adult patients with recurrent glioblastoma.
• Hepatocellular Carcinoma：
  Bevacizumab in combination with atezolizumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
• Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer：
  Bevacizumab in combination with carboplatin and paclitaxel is used as first‑line treatment for patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.
• Cervical Cancer：
  Bevacizumab in combination with paclitaxel and cisplatin, or with paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

(This product is a prescription drug, please take this drug with doctor’s prescription and under doctor’s instruction)